EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle

Rosa Bellavita iD, Marina Prisco iD, Sara Palladino iD, Teresa Barra iD, Federica Donadio iD, Emanuela Esposito iD, Rodolfo Esposito iD, Giuliana Panico iD, Jessica Pisano, Paola Venditti, Salvatore Valiante iD, Annarita Falanga iD und 3 weitere

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c17607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Rosa Bellavita und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy. Hauptthemen laut MEDLINE: Temozolomide, Pyruvates, Glioblastoma, Nanofibers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell???Istruzione, dell???Universit?? e della Ricerca, Universit?? degli Studi di Napoli Federico II, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combination therapy has shown promise in treating aggressive cancers by using several drugs simultaneously to target different biological pathways, with the added benefit of potentially reducing toxicity. Given the critical role of mitochondrial dysfunction in tumor progression, targeting mitochondrial metabolism represents a promising therapeutic avenue. In this study, we developed a mitochondria-targeted nanofiber based on self-assembling peptides, engineered to co-deliver two complementary therapeutic agents for glioblastoma treatment. The nanofiber carries 1,3-bromopyruvate (BrP), a glycolysis inhibitor, and temozolomide, an alkylating chemotherapeutic, conjugated via a matrix metalloproteinase-9 (MMP-9)-responsive linker for controlled, on-demand release. To enhance selectivity for glioblastoma cells, the nanofiber surface was functionalized with the targeting peptide falGea binding specifically to EGFRvIII, commonly overexpressed in tumor cells, and gH625, a cell-penetrating peptide known to facilitate the blood-brain barrier (BBB) transport. The nanofibers were comprehensively characterized for their aggregation behavior, structural stability, and morphology. Mitochondrial targeting and functional effects were evaluated by using isolated rat brain mitochondria. Therapeutic efficacy was assessed in U-87 MG glioblastoma cells cultured in both 2D and 3D systems. Additionally, BBB permeability was examined by using a dynamic 3D in vitro BBB model, demonstrating the transport-enhancing role of gH625. These findings support the potential of multifunctional, mitochondria-targeted nanofibers as an effective platform for glioblastoma therapy, offering both precision targeting and enhanced drug delivery across the BBB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomidePyruvatesGlioblastomaNanofibersAntineoplastic AgentsDrug CarriersHumansAnimalsRatsCell Line, TumorMitochondriaBlood-Brain BarrierCell-Penetrating Peptides

Stichwörter der Autor:innen

blood−brain barrierglioblastomamitochondrial targetingnanofiberself-assembling peptides

Substanzen

bromopyruvateTemozolomidePyruvatesCell-Penetrating PeptidesAntineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • Department of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.
  • Department of Biology,University of Napoli Federico II, Via Cintia, 80126 Naples, Italy.
  • Institute of Applied Sciences and Intelligent Systems (ISASI), Naples Cryo Electron Microscopy Laboratory - EYE LAB, National Research Council (CNR), Via Pietro Castellino 111, 80131 Naples, Italy.
  • Department of Chemical Sciences, University of Napoli Federico II, and CSGI (Unit of Naples), Via Cintia, 80126 Naples, Italy.
  • Department of Agricultural Sciences, University of Naples Federico II, Via Università 100, 80055 Portici, Italy.

ORCID-Profile: Rosa Bellavita, Marina Prisco, Sara Palladino, Teresa Barra, Federica Donadio, Emanuela Esposito, Rodolfo Esposito, Giuliana Panico, Salvatore Valiante, Annarita Falanga, Gerardino D'Errico, Assunta Lombardi, Stefania Galdiero

Förderung

  • Ministero dell???Istruzione, dell???Universit?? e della Ricerca
  • Universit?? degli Studi di Napoli Federico II
  • European Commission

Zitieren

APA

Bellavita, R., Prisco, M., Palladino, S., Barra, T., Donadio, F., Esposito, E., Esposito, R., Panico, G., Pisano, J., Venditti, P., Valiante, S., Falanga, A., D'Errico, G., Lombardi, A., & Galdiero, S. (2025). Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c17607

Vancouver

Bellavita R, Prisco M, Palladino S, Barra T, Donadio F, Esposito E, et al. Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c17607

BibTeX
@article{Bellavita2025,
  author = {Bellavita, Rosa and Prisco, Marina and Palladino, Sara and Barra, Teresa and Donadio, Federica and Esposito, Emanuela and Esposito, Rodolfo and Panico, Giuliana and Pisano, Jessica and Venditti, Paola and Valiante, Salvatore and Falanga, Annarita and D'Errico, Gerardino and Lombardi, Assunta and Galdiero, Stefania},
  title = {Synergistic Cancer Metabolic Therapy via Co-Delivery of 3-Bromopyruvate and Temozolomide with a Supramolecular Shuttle},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c17607}
}
Kostenlos starten →